CYP2C19 and cancer: In summary, the IHC data from tumors and lungs suggest that the expression of FABP4, FABP5, or CYP2C19 is not solely come from cancer cells but also from resident or infiltrating stromal cells in tumor and lung microenvironments, affecting TNBC tumor growth or metastasis.